{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T23:21:15Z","timestamp":1775604075867,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["6253"],"award-info":[{"award-number":["6253"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Breast cancer survivors are at risk for contralateral breast cancer (CBC), with the consequent burden of further treatment and potentially less favorable prognosis. We aimed to develop and validate a CBC risk prediction model and evaluate its applicability for clinical decision-making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included data of 132,756 invasive non-metastatic breast cancer patients from 20 studies with 4682 CBC events and a median follow-up of 8.8\u2009years. We developed a multivariable Fine and Gray prediction model (PredictCBC-1A) including patient, primary tumor, and treatment characteristics and<jats:italic>BRCA1\/2<\/jats:italic>germline mutation status, accounting for the competing risks of death and distant metastasis. We also developed a model without<jats:italic>BRCA1\/2<\/jats:italic>mutation status (PredictCBC-1B) since this information was available for only 6% of patients and is routinely unavailable in the general breast cancer population. Prediction performance was evaluated using calibration and discrimination, calculated by a time-dependent area under the curve (AUC) at 5 and 10\u2009years after diagnosis of primary breast cancer, and an internal-external cross-validation procedure. Decision curve analysis was performed to evaluate the net benefit of the model to quantify clinical utility.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the multivariable model,<jats:italic>BRCA1\/2<\/jats:italic>germline mutation status, family history, and systemic adjuvant treatment showed the strongest associations with CBC risk. The AUC of PredictCBC-1A was 0.63 (95% prediction interval (PI) at 5\u2009years, 0.52\u20130.74; at 10\u2009years, 0.53\u20130.72). Calibration-in-the-large was\u2009-0.13 (95% PI:\u2009-1.62\u20131.37), and the calibration slope was 0.90 (95% PI: 0.73\u20131.08). The AUC of Predict-1B at 10\u2009years was 0.59 (95% PI: 0.52\u20130.66); calibration was slightly lower. Decision curve analysis for preventive contralateral mastectomy showed potential clinical utility of PredictCBC-1A between thresholds of 4\u201310% 10-year CBC risk for<jats:italic>BRCA1\/2<\/jats:italic>mutation carriers and non-carriers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We developed a reasonably calibrated model to predict the risk of CBC in women of European-descent; however, prediction accuracy was moderate. Our model shows potential for improved risk counseling, but decision-making regarding contralateral preventive mastectomy, especially in the general breast cancer population where limited information of the mutation status in<jats:italic>BRCA1\/2<\/jats:italic>is available, remains challenging.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13058-019-1221-1","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T19:03:02Z","timestamp":1576609382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Prediction and clinical utility of a contralateral breast cancer risk model"],"prefix":"10.1186","volume":"21","author":[{"given":"Daniele","family":"Giardiello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewout W.","family":"Steyerberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hauptmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel A.","family":"Adank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delal","family":"Akdeniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Blomqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stig E.","family":"Bojesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjeet K.","family":"Bolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00ebl","family":"Brinkhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Chang-Claude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Czene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Devilee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison M.","family":"Dunning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas F.","family":"Easton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana M.","family":"Eccles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonine","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Flyger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Garc\u00eda-Closas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"Haeberle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Haiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Hopper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Jakubowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renske","family":"Keeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diether","family":"Lambrechts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loic","family":"Le Marchand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Lindblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Lubi\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Manoochehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heli","family":"Nevanlinna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hester S. A.","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"Pelders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D. P.","family":"Pharoah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitul","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent T. H. B. M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa C.","family":"Southey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Tapper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob A. E. M.","family":"Tollenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra J.","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolien H. M.","family":"van Deurzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora E.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"van Ongeval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Van\u2019t Veer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Wendt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter J.","family":"Westenend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maartje J.","family":"Hooning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjanka K.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"issue":"6","key":"1221_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1221_CR2","unstructured":"Survival and prevalence of cancer. https:\/\/www.cijfersoverkanker.nl. Accessed Mar 2019."},{"issue":"1","key":"1221_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-007-9709-2","volume":"110","author":"M Schaapveld","year":"2008","unstructured":"Schaapveld M, Visser O, Louwman WJ, Willemse PH, de Vries EG, van der Graaf WT, Otter R, Coebergh JW, van Leeuwen FE. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2008;110(1):189\u201397.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"1221_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/jnci\/djq058","volume":"102","author":"DJ Brenner","year":"2010","unstructured":"Brenner DJ. Contralateral second breast cancers: prediction and prevention. J Natl Cancer Inst. 2010;102(7):444\u20135.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1221_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1200\/JCO.2015.62.3942","volume":"34","author":"AJ van den Broek","year":"2016","unstructured":"van den Broek AJ, van \u2018t Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, Smit VT, Cornelisse CJ, van Beek M, Janssen-Heijnen ML, et al. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1\/2 mutation carriers. J Clin Oncol. 2016;34(5):409\u201318.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1221_CR6","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1200\/JCO.2009.24.2495","volume":"28","author":"KE Malone","year":"2010","unstructured":"Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28(14):2404\u201310.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1221_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-013-2583-1","volume":"140","author":"DG Evans","year":"2013","unstructured":"Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, Howell A. Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer. Breast Cancer Res Treat. 2013;140(1):135\u201342.","journal-title":"Breast Cancer Res Treat"},{"issue":"35","key":"1221_CR8","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","volume":"27","author":"MK Graeser","year":"2009","unstructured":"Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27(35):5887\u201392.","journal-title":"J Clin Oncol"},{"issue":"35","key":"1221_CR9","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1200\/JCO.2012.42.7336","volume":"30","author":"M Weischer","year":"2012","unstructured":"Weischer M, Nordestgaard BG, Pharoah P, Bolla MK, Nevanlinna H, Van't Veer LJ, Garcia-Closas M, Hopper JL, Hall P, Andrulis IL, et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol. 2012;30(35):4308\u201316.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1221_CR10","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA"},{"issue":"1","key":"1221_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1001\/jama.2018.18942","volume":"321","author":"SM Domchek","year":"2019","unstructured":"Domchek SM. Risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers: a complex discussion. JAMA. 2019;321(1):27.","journal-title":"JAMA"},{"issue":"10","key":"1221_CR12","first-page":"855","volume":"8","author":"Y Chen","year":"1999","unstructured":"Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomark Prev. 1999;8(10):855\u201361.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1221_CR13","doi-asserted-by":"crossref","unstructured":"Kramer I, Schaapveld M, Oldenburg HSA, Sonke GS, McCool D, van Leeuwen FE, Van de Vijver KK, Russell NS, Linn SC, Siesling S, et al. The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype. J Natl Cancer Inst. 2019;111(7):709\u201318.","DOI":"10.1093\/jnci\/djz010"},{"issue":"12","key":"1221_CR14","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1245\/s10434-015-4442-2","volume":"22","author":"PR Portschy","year":"2015","unstructured":"Portschy PR, Abbott AM, Burke EE, Nzara R, Marmor S, Kuntz KM, Tuttle TM. Perceptions of contralateral breast cancer risk: a prospective, longitudinal study. Ann Surg Oncol. 2015;22(12):3846\u201352.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"1221_CR15","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1016\/S1470-2045(13)70047-0","volume":"14","author":"JA Murphy","year":"2013","unstructured":"Murphy JA, Milner TD, O'Donoghue JM. Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol. 2013;14(7):e262\u20139.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1221_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-016-4039-x","volume":"161","author":"M Chowdhury","year":"2017","unstructured":"Chowdhury M, Euhus D, Onega T, Biswas S, Choudhary PK. A model for individualized risk prediction of contralateral breast cancer. Breast Cancer Res Treat. 2017;161(1):153\u201360.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1221_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10549-018-4763-5","volume":"170","author":"Marzana Chowdhury","year":"2018","unstructured":"Chowdhury M, Euhus D, Arun B, Umbricht C, Biswas S, Choudhary P. Validation of a personalized risk prediction model for contralateral breast cancer. Breast Cancer Res Treat. 2018;170:415. https:\/\/link.springer.com\/article\/10.1007\/s10549-018-4763-5#citeas.","journal-title":"Breast Cancer Research and Treatment"},{"key":"1221_CR18","doi-asserted-by":"publisher","first-page":"i6","DOI":"10.1136\/bmj.i6","volume":"352","author":"AJ Vickers","year":"2016","unstructured":"Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ. 2016;352:i6.","journal-title":"BMJ"},{"issue":"7678","key":"1221_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature24284","volume":"551","author":"K Michailidou","year":"2017","unstructured":"Michailidou K, Lindstrom S, Dennis J, Beesley J, Hui S, Kar S, Lemacon A, Soucy P, Glubb D, Rostamianfar A, et al. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017;551(7678):92\u20134.","journal-title":"Nature"},{"issue":"1","key":"1221_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1200\/JCO.2006.06.3024","volume":"25","author":"MK Schmidt","year":"2007","unstructured":"Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 2007;25(1):64\u20139.","journal-title":"J Clin Oncol"},{"key":"1221_CR21","doi-asserted-by":"crossref","unstructured":"Schmidt MK, van den Broek AJ, Tollenaar RA, Smit VT, Westenend PJ, Brinkhuis M, Oosterhuis WJ, Wesseling J, Janssen-Heijnen ML, Jobsen JJ, et al. Breast cancer survival of BRCA1\/BRCA2 mutation carriers in a hospital-based cohort of young women. J Natl Cancer Inst. 2017;109(8). https:\/\/academic.oup.com\/jnci\/article\/109\/8\/djw329\/3064570.","DOI":"10.1093\/jnci\/djw329"},{"issue":"3","key":"1221_CR22","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s10549-013-2588-9","volume":"139","author":"A Font-Gonzalez","year":"2013","unstructured":"Font-Gonzalez A, Liu L, Voogd AC, Schmidt MK, Roukema JA, Coebergh JW, de Vries E, Soerjomataram I. Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands. Breast Cancer Res Treat. 2013;139(3):811\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1221_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00439-011-1074-x","volume":"130","author":"PH Riegman","year":"2011","unstructured":"Riegman PH, van Veen EB. Biobanking residual tissues. Hum Genet. 2011;130(3):357\u201368.","journal-title":"Hum Genet"},{"key":"1221_CR24","volume-title":"Human tissue and medical research: code of conduct for responsible use","author":"Foundation Federation of Dutch Medical Scientific Societies","year":"2011","unstructured":"Foundation Federation of Dutch Medical Scientific Societies: Human tissue and medical research: code of conduct for responsible use. 2011."},{"issue":"28","key":"1221_CR25","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1200\/JCO.2011.39.3645","volume":"30","author":"V Vichapat","year":"2012","unstructured":"Vichapat V, Garmo H, Holmqvist M, Liljegren G, Warnberg F, Lambe M, Fornander T, Adolfsson J, Luchtenborg M, Holmberg L. Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. J Clin Oncol. 2012;30(28):3478\u201385.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1221_CR26","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ejca.2011.05.004","volume":"47","author":"V Vichapat","year":"2011","unstructured":"Vichapat V, Gillett C, Fentiman IS, Tutt A, Holmberg L, Luchtenborg M. Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways. Eur J Cancer. 2011;47(13):1919\u201327.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1221_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1005765403093","volume":"44","author":"L Mariani","year":"1997","unstructured":"Mariani L, Coradini D, Biganzoli E, Boracchi P, Marubini E, Pilotti S, Salvadori B, Silvestrini R, Veronesi U, Zucali R, et al. Prognostic factors for metachronous contralateral breast cancer: a comparison of the linear Cox regression model and its artificial neural network extension. Breast Cancer Res Treat. 1997;44(2):167\u201378.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1221_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13058-017-0874-x","volume":"19","author":"AS Reiner","year":"2017","unstructured":"Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, Knight JA, Hsu L, Concannon P, Mellemkjaer L, et al. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. Breast Cancer Res. 2017;19(1):83.","journal-title":"Breast Cancer Res"},{"key":"1221_CR29","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1186\/s40064-015-1642-y","volume":"4","author":"JS Sisti","year":"2015","unstructured":"Sisti JS, Bernstein JL, Lynch CF, Reiner AS, Mellemkjaer L, Brooks JD, Knight JA, Bernstein L, Malone KE, Woods M, et al. Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study. Springerplus. 2015;4:825.","journal-title":"Springerplus"},{"issue":"8","key":"1221_CR30","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1200\/JCO.1993.11.8.1545","volume":"11","author":"EA Healey","year":"1993","unstructured":"Healey EA, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol. 1993;11(8):1545\u201352.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1221_CR31","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S0360-3016(03)00203-7","volume":"56","author":"X Gao","year":"2003","unstructured":"Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56(4):1038\u201345.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"1221_CR32","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1002\/cam4.890","volume":"5","author":"JD Brooks","year":"2016","unstructured":"Brooks JD, John EM, Mellemkjaer L, Lynch CF, Knight JA, Malone KE, Reiner AS, Bernstein L, Liang X, Shore RE, et al. Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer. Cancer Med. 2016;5(11):3282\u201391.","journal-title":"Cancer Med"},{"issue":"1","key":"1221_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13058-018-0948-4","volume":"20","author":"JA Knight","year":"2018","unstructured":"Knight JA, Blackmore KM, Fan J, Malone KE, John EM, Lynch CF, Vachon CM, Bernstein L, Brooks JD, Reiner AS, et al. The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. Breast Cancer Res. 2018;20(1):23.","journal-title":"Breast Cancer Res"},{"key":"1221_CR34","first-page":"901046","volume":"2015","author":"NN Basu","year":"2015","unstructured":"Basu NN, Barr L, Ross GL, Evans DG. Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies. Int J Surg Oncol. 2015;2015:901046.","journal-title":"Int J Surg Oncol"},{"key":"1221_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2018.11.005","volume":"44","author":"D Akdeniz","year":"2018","unstructured":"Akdeniz D, Schmidt MK, Seynaeve CM, McCool D, Giardiello D, van den Broek AJ, Hauptmann M, Steyerberg EW, Hooning MJ. Risk factors for metachronous contralateral breast cancer: a systematic review and meta-analysis. Breast. 2018;44:1\u201314.","journal-title":"Breast"},{"issue":"6","key":"1221_CR36","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471\u20134.","journal-title":"Ann Surg Oncol"},{"key":"1221_CR37","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2017. http:\/\/www.R-project.org\/, https:\/\/cran.r-project.org\/doc\/FAQ\/R-FAQ.html#Citing-R."},{"issue":"2","key":"1221_CR38","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/SLA.0000000000002804","volume":"270","author":"AJ van den Broek","year":"2019","unstructured":"van den Broek AJ, Schmidt MK, van \u2018t Veer LJ, HSA O, Rutgers EJ, Russell NS, Smit V, Voogd AC, Koppert LB, Siesling S, et al. Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1\/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients. Ann Surg. 2019;270(2):364\u201372.","journal-title":"Ann Surg"},{"issue":"28","key":"1221_CR39","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1002\/sim.5894","volume":"32","author":"M Resche-Rigon","year":"2013","unstructured":"Resche-Rigon M, White IR, Bartlett JW, Peters SA, Thompson SG, Group P-IS. Multiple imputation for handling systematically missing confounders in meta-analysis of individual participant data. Stat Med. 2013;32(28):4890\u2013905.","journal-title":"Stat Med"},{"key":"1221_CR40","volume-title":"Flexible imputation of missing data","author":"B Sv","year":"2012","unstructured":"Sv B. Flexible imputation of missing data. Boca Raton: CRC Press; 2012."},{"issue":"1","key":"1221_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1541-0420.2010.01420.x","volume":"67","author":"RB Geskus","year":"2011","unstructured":"Geskus RB. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring. Biometrics. 2011;67(1):39\u201349.","journal-title":"Biometrics"},{"issue":"446","key":"1221_CR42","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496\u2013509.","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"1221_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2307\/2531021","volume":"39","author":"DA Schoenfeld","year":"1983","unstructured":"Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39(2):499\u2013503.","journal-title":"Biometrics"},{"key":"1221_CR44","volume-title":"Statistical analysis with missing data","author":"RJA Little","year":"1987","unstructured":"Little RJA, Rubin DB. Statistical analysis with missing data. New York: Wiley; 1987."},{"issue":"20","key":"1221_CR45","doi-asserted-by":"publisher","first-page":"403","DOI":"10.21037\/atm.2017.07.27","volume":"5","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Geskus RB, Kattan MW, Zhang H, Liu T. Nomogram for survival analysis in the presence of competing risks. Ann Transl Med. 2017;5(20):403.","journal-title":"Ann Transl Med"},{"key":"1221_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jclinepi.2015.04.005","volume":"69","author":"EW Steyerberg","year":"2016","unstructured":"Steyerberg EW, Harrell FE Jr. Prediction models need appropriate internal, internal-external, and external validation. J Clin Epidemiol. 2016;69:245\u20137.","journal-title":"J Clin Epidemiol"},{"key":"1221_CR47","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jclinepi.2016.05.007","volume":"79","author":"PC Austin","year":"2016","unstructured":"Austin PC, van Klaveren D, Vergouwe Y, Nieboer D, Lee DS, Steyerberg EW. Geographic and temporal validity of prediction models: different approaches were useful to examine model performance. J Clin Epidemiol. 2016;79:76\u201385.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"1221_CR48","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/sim.6787","volume":"35","author":"GS Collins","year":"2016","unstructured":"Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med. 2016;35(2):214\u201326.","journal-title":"Stat Med"},{"key":"1221_CR49","volume-title":"Clinical prediction models: a practical approach to development, validation and updating","author":"EW Steyerberg","year":"2010","unstructured":"Steyerberg EW. Clinical prediction models: a practical approach to development, validation and updating. New York: Springer; 2010."},{"issue":"30","key":"1221_CR50","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","volume":"32","author":"P Blanche","year":"2013","unstructured":"Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381\u201397.","journal-title":"Stat Med"},{"key":"1221_CR51","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2015.05.009","volume":"69","author":"KI Snell","year":"2016","unstructured":"Snell KI, Hua H, Debray TP, Ensor J, Look MP, Moons KG, Riley RD. Multivariate meta-analysis of individual participant data helped externally validate the performance and implementation of a prediction model. J Clin Epidemiol. 2016;69:40\u201350.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"1221_CR52","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26(6):565\u201374.","journal-title":"Med Decis Mak"},{"issue":"21","key":"1221_CR53","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1200\/JCO.2015.65.5654","volume":"34","author":"KF Kerr","year":"2016","unstructured":"Kerr KF, Brown MD, Zhu K, Janes H. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol. 2016;34(21):2534\u201340.","journal-title":"J Clin Oncol"},{"key":"1221_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1472-6947-8-53","volume":"8","author":"AJ Vickers","year":"2008","unstructured":"Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"3","key":"1221_CR55","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","volume":"136","author":"BA Heemskerk-Gerritsen","year":"2015","unstructured":"Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Collee JM, Jansen L, Kets CM, Keymeulen KB, Koppert LB, Meijers-Heijboer HE, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136(3):668\u201377.","journal-title":"Int J Cancer"},{"issue":"5","key":"1221_CR56","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/jnci\/93.5.358","volume":"93","author":"B Rockhill","year":"2001","unstructured":"Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358\u201366.","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"1221_CR57","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/jnci\/djj501","volume":"98","author":"JG Elmore","year":"2006","unstructured":"Elmore JG, Fletcher SW. The risk of cancer risk prediction: \u201cwhat is my risk of getting breast cancer\u201d? J Natl Cancer Inst. 2006;98(23):1673\u20135.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1221_CR58","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1186\/bcr2464","volume":"12","author":"GC Wishart","year":"2010","unstructured":"Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12(1):R1.","journal-title":"Breast Cancer Res"},{"issue":"25","key":"1221_CR59","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1200\/JCO.2007.14.4501","volume":"26","author":"LJ Goldstein","year":"2008","unstructured":"Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26(25):4063\u201371.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1221_CR60","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/ejhg.2014.161","volume":"23","author":"AJ van den Broek","year":"2015","unstructured":"van den Broek AJ, de Ruiter K, van \u2018t Veer LJ, Tollenaar RA, van Leeuwen FE, Verhoef S, Schmidt MK. Evaluation of the Dutch BRCA1\/2 clinical genetic center referral criteria in an unselected early breast cancer population. Eur J Hum Genet. 2015;23(5):588\u201395.","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"1221_CR61","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/jnci\/djy013","volume":"110","author":"Mitchell H Gail","year":"2018","unstructured":"Gail MH, Pfeiffer RM. Breast cancer risk model requirements for counseling, prevention, and screening. J Natl Cancer Inst. 2018;110(9):994\u20131002.","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"2","key":"1221_CR62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12609-018-0271-1","volume":"10","author":"M O'Donnell","year":"2018","unstructured":"O'Donnell M. Estimating contralateral breast cancer risk. Current Breast Cancer Rep. 2018;10(2):91\u20137.","journal-title":"Current Breast Cancer Rep"},{"issue":"2","key":"1221_CR63","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ijc.31914","volume":"144","author":"MC van Maaren","year":"2019","unstructured":"van Maaren MC, de Munck L, Strobbe LJA, Sonke GS, Westenend PJ, Smidt ML, Poortmans PMP, Siesling S. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study. Int J Cancer. 2019;144(2):263\u201372.","journal-title":"Int J Cancer"},{"issue":"17","key":"1221_CR64","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1016\/j.ejca.2009.08.007","volume":"45","author":"W Lu","year":"2009","unstructured":"Lu W, Schaapveld M, Jansen L, Bagherzadegan E, Sahinovic MM, Baas PC, Hanssen LM, van der Mijle HC, Brandenburg JD, Wiggers T, et al. The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer. Eur J Cancer. 2009;45(17):3000\u20137.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1221_CR65","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/jcm7060133","volume":"7","author":"Zhenchong Xiong","year":"2018","unstructured":"Xiong Z, Yang L, Deng G, Huang X, Li X, Xie X, Wang J, Shuang Z, Wang X. Patterns of occurrence and outcomes of contralateral breast cancer: analysis of SEER data. J Clin Med. 2018;7(6):133. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6025574\/.","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"1221_CR66","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13058-016-0726-0","volume":"18","author":"R Langballe","year":"2016","unstructured":"Langballe R, Mellemkjaer L, Malone KE, Lynch CF, John EM, Knight JA, Bernstein L, Brooks J, Andersson M, Reiner AS, et al. Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE study. Breast Cancer Res. 2016;18(1):65.","journal-title":"Breast Cancer Res"},{"key":"1221_CR67","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12957-015-0638-y","volume":"13","author":"NN Basu","year":"2015","unstructured":"Basu NN, Ross GL, Evans DG, Barr L. The Manchester guidelines for contralateral risk-reducing mastectomy. World J Surg Oncol. 2015;13:237.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"1221_CR68","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12874-016-0231-2","volume":"16","author":"D Nieboer","year":"2016","unstructured":"Nieboer D, Vergouwe Y, Ankerst DP, Roobol MJ, Steyerberg EW. Improving prediction models with new markers: a comparison of updating strategies. BMC Med Res Methodol. 2016;16(1):128.","journal-title":"BMC Med Res Methodol"},{"key":"1221_CR69","doi-asserted-by":"publisher","first-page":"e4181","DOI":"10.1136\/bmj.e4181","volume":"344","author":"GS Collins","year":"2012","unstructured":"Collins GS, Altman DG. Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2. BMJ. 2012;344:e4181.","journal-title":"BMJ"},{"key":"1221_CR70","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jclinepi.2019.02.016","volume":"110","author":"P Madley-Dowd","year":"2019","unstructured":"Madley-Dowd P, Hughes R, Tilling K, Heron J. The proportion of missing data should not be used to guide decisions on multiple imputation. J Clin Epidemiol. 2019;110:63\u201373.","journal-title":"J Clin Epidemiol"},{"issue":"34","key":"1221_CR71","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1200\/JCO.2017.73.6314","volume":"35","author":"CP Childers","year":"2017","unstructured":"Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35(34):3800\u20136.","journal-title":"J Clin Oncol"},{"key":"1221_CR72","doi-asserted-by":"publisher","first-page":"l737","DOI":"10.1136\/bmj.l737","volume":"365","author":"LJ Bonnett","year":"2019","unstructured":"Bonnett LJ, Snell KIE, Collins GS, Riley RD. Guide to presenting clinical prediction models for use in clinical settings. BMJ. 2019;365:l737.","journal-title":"BMJ"},{"issue":"7","key":"1221_CR73","doi-asserted-by":"publisher","first-page":"e0132614","DOI":"10.1371\/journal.pone.0132614","volume":"10","author":"V Van Belle","year":"2015","unstructured":"Van Belle V, Van Calster B. Visualizing risk prediction models. PLoS One. 2015;10(7):e0132614.","journal-title":"PLoS One"},{"issue":"4","key":"1221_CR74","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","volume":"16","author":"VP Balachandran","year":"2015","unstructured":"Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173\u201380.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1221_CR75","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","volume":"104","author":"N Mavaddat","year":"2019","unstructured":"Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet. 2019;104(1):21\u201334.","journal-title":"Am J Hum Genet"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-019-1221-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-019-1221-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-019-1221-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T19:44:55Z","timestamp":1722195895000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-019-1221-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1221"],"URL":"https:\/\/doi.org\/10.1186\/s13058-019-1221-1","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"7 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Each study was approved by its institutional ethical review board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}